Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindro...
Q2 2026
Aug 6, 2026
Q1 2026
May 11, 2026
FY 2025
Feb 26, 2026
Q4 2025
Q3 2025
Nov 6, 2025
